Literature DB >> 11493717

Lung involvement and enzyme replacement therapy in Gaucher's disease.

O Goitein1, D Elstein, A Abrahamov, I Hadas-Halpern, E Melzer, E Kerem, A Zimran.   

Abstract

Symptomatic lung involvement in Gaucher's disease is relatively rare, being restricted to patients with other severe manifestations. We describe our experience in eight of 411 patients in our referral clinic, who presented with prominent pulmonary signs or symptoms. There were four adults and four children; all have been successfully treated with enzyme replacement therapy. Routine means of monitoring pulmonary status including clinical assessment, chest X-ray, pulmonary function tests, and high-resolution CT (HRCT) were used. Enzyme treatment resulted in decreased hepatosplenomegaly, improved haematological parameters, and increased well-being; There was decreased clubbing and decreased dyspnoea in some of the patients, although on radiology, lung pathology had not normalized. All four children showed improved respiratory compliance, with significant improvement of the radiological findings in one and unchanged disease in the others. Two adults showed improvement in oxygen saturation but worsening of pulmonary hypertension. On chest X-ray, both had increased interstitial markings; one had gradual progression of pulmonary artery accentuation and fine interstitial stable pattern on HRCT. The other two adults had no change in lung function or on chest X-ray, but on HRCT there was apparent improvement in one patient. There is great heterogeneity in presentation and response to enzyme therapy in patients with Gaucher's disease and symptomatic lung involvement. Clinically, some benefited significantly from enzyme therapy, but in contrast to the dramatic reduction in organomegaly, there was no normalization in pulmonary function or lung architecture.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493717     DOI: 10.1093/qjmed/94.8.407

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  19 in total

Review 1.  Genetic interstitial lung disease.

Authors:  Megan Stuebner Devine; Christine Kim Garcia
Journal:  Clin Chest Med       Date:  2011-12-06       Impact factor: 2.878

2.  Pulmonary hemorrhage in type 3 Gaucher disease: a case report.

Authors:  Ashok Vellodi; Michael Ashworth; Niamh Finnegan; Colin Wallis
Journal:  J Inherit Metab Dis       Date:  2010-08-06       Impact factor: 4.982

Review 3.  Imaging of Gaucher disease.

Authors:  William L Simpson; George Hermann; Manisha Balwani
Journal:  World J Radiol       Date:  2014-09-28

Review 4.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 5.  Imaging of macrophage-related lung diseases.

Authors:  Katharina Marten; David M Hansell
Journal:  Eur Radiol       Date:  2005-01-05       Impact factor: 5.315

Review 6.  New prospects for the treatment of lysosomal storage diseases.

Authors:  Raphael Schiffmann; Roscoe O Brady
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Imaging of Childhood Interstitial Lung Disease.

Authors:  R Paul Guillerman
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2010-03       Impact factor: 1.349

Review 8.  Gaucher disease: pediatric concerns.

Authors:  Deborah Elstein; Aya Abrahamov; Altoon Dweck; Irith Hadas-Halpern; Ari Zimran
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Randomized, controlled trial of miglustat in Gaucher's disease type 3.

Authors:  Raphael Schiffmann; Edmond J Fitzgibbon; Chris Harris; Catherine DeVile; Elin H Davies; Larry Abel; Ivo N van Schaik; William Benko; Margaret Timmons; Markus Ries; Ashok Vellodi
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

Review 10.  Gaucher disease and the clinical experience with substrate reduction therapy.

Authors:  Ari Zimran; Deborah Elstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.